Genetic diagnosis and prognosis of Alzheimer's disease: Challenges and opportunities

Expert Review of Molecular Diagnostics

Volumn 15, Issue 3, 2015, Pages 339-348

  Reitz, Christiane ^a  

^a Vagelos College of Physicians and Surgeons   (United States)

Author keywords

Alzheimer's disease; diagnosis; genomics; prognosis; therapy

Indexed keywords

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; DISEASE COURSE; GENETIC ASSOCIATION; BIOLOGY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN; PROCEDURES; PROGNOSIS;

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BIOMARKERS; COMPUTATIONAL BIOLOGY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; PROGNOSIS;

EID: 84923360271     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1002469     Document Type: Review

References (118)

1. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. N Engl J Med 2013;368(14): 1326-34
2. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6(2):158-94
3. Roe CM, Fagan AM, Grant EA, et al. CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. Neurology 2013; 81(23):2028-31
4. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013;74(6): 905-13
5. Laske C. Blood-based biomarkers in Alzheimer disease: where are we now and where have we to go? JAMA Neurol 2013; 70(1):133
6. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349(6311):704-6
7. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269(5226):973-7
8. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375(6534):754-60
9. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
10. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008;283(44):29615-19
11. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012;33(9):1340-4. Available from: www.molgen.vib-ua.be/ADMutations/
12. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 2012;33(3):437-56. Available from: www.molgen.ua.ac.be/admutations/
13. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323(5920): 1473-7
14. Remes AM, Finnila S, Mononen H, et al. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 2004;63(2):234-40
15. Rovelet-Lecrux A, Frebourg T, Tuominen H, et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007;78(10):1158-9
16. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006;129(Pt 11): 2977-83
17. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1(5):345-7
18. Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008;63(3):377-87
19. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001;4(9):887-93
20. Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J 2012;31(10):2261-74
21. Lalli MA, Cox HC, Arcila ML, et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. Alzheimers Dement 2014;10(5 Suppl): S277-83
22. Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997; 277(10):793-9
23. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11(12):1048-56
24. Benitez BA, Karch CM, Cai Y, et al. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOEepsilon4 carriers. PLoS Genet 2013;9(8): e1003685
25. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7(2):e31039
26. Kim M, Suh J, Romano D, et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 2009;18(20):3987-96
27. Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. Neuron 2013;80(2):385-401
28. Lander ES. The new genomics: global views of biology. Science 1996;274(5287):536-9
29. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001;69(1):124-37
30. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461(7265):747-53
31. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ 1994; 309(6955):636-8
32. Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurol 1999; 53(2):321-31
33. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123):921-3
34. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39(1):62-70
35. Holmes C, Levy R, McLoughlin DM, et al. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;61(6):580-3
36. Kurz A, Altland K, Lautenschlager N, et al. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. J Neurol 1996;243(6):452-6
37. Murman DL, Foster NL, Kilgore SP, et al. Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. Dementia 1996;7(5):251-5
38. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342(8873): 697-9
39. Roses AD. Alzheimer's disease: the genetics of risk. Hosp Pract (Minneap) 1997;32(7): 58-63
40. Barabash A, Marcos A, Ancin I, et al. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009;30(8):1254-64
41. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273(16):1274-8
42. Sasaki M, Kodama C, Hidaka S, et al. Prevalence of four subtypes of mild cognitive impairment and APOE in a Japanese community. Int J Geriatr Psychiatry 2009;24(10):1119-26
43. Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 2007;165(11): 1231-8
44. Blom ES, Giedraitis V, Zetterberg H, et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 2009;27(5):458-64
45. Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005;62(6):975-80
46. Hamalainen A, Grau-Olivares M, Tervo S, et al. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. Neurodegener Dis 2008;5(3-4):186-9
47. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004;171(8): 863-7
48. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52(7): 1397-403
49. Ramakers IH, Visser PJ, Aalten P, et al. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dement Geriatr Cogn Disord 2008;26(2):101-8
50. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46(1):149-54
51. Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55(7):964-8
52. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996;46(3): 673-7
53. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41(10):1088-93
54. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43(5):436-41
55. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303(18):1832-40
56. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41(10): 1094-9
57. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45(12):1452-8
58. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43(5):429-35
59. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168-77
60. Reitz C, Cheng R, Rogaeva E, et al. Meta-analysis of the association between variants in SORL1 and Alzheimer's disease Arch Neurol. 2011;68(1):99-106
61. Nuutinen T, Suuronen T, Kauppinen A, et al. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61(2):89-104
62. Wollmer MA, Sleegers K, Ingelsson M, et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 2007;8(3):179-88
63. Pant S, Sharma M, Patel K, et al. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol 2009;11(12):1399-410
64. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999;10(8):2687-702
65. Crehan H, Holton P, Wray S, et al. Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology 2012; 217(2):244-50
66. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42(2): 447-9
67. Yamazaki T, Masuda J, Omori T, et al. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci 2009;122(Pt 2):243-55
68. Holen HL, Nustad K, Aasheim HC. Activation of EphA receptors on CD4 +CD45RO+ memory cells stimulates migration. J Leukoc Biol 2010;87(6): 1059-68
69. Sakamoto A, Sugamoto Y, Tokunaga Y, et al. Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells. J Int Med Res 2011;39(2):522-7
70. Lehtonen S, Zhao F, Lehtonen E. CD2-associated protein directly interacts with the actin cytoskeleton. Am J Physiol Renal Physiol 2002;283(4):F734-43
71. Dustin ML, Olszowy MW, Holdorf AD, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998;94(5):667-77
72. Chan SL, Kim WS, Kwok JB, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem 2008;106(2): 793-804
73. Tanaka N, Abe-Dohmae S, Iwamoto N, et al. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb 2011;18(4):274-81
74. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013;309(14):1483-92
75. Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014;505(7484):550-4
76. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368(2):117-27
77. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368(2):107-16
78. Reitz C, Mayeux R. TREM2 and neurodegenerative disease. N Engl J Med 2013;369(16):1564-5
79. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003;3(6): 445-53
80. Paloneva J, Mandelin J, Kiialainen A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003; 198(4):669-75
81. Cuyvers E, Bettens K, Philtjens S, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 2014;35(3):726 e711-19
82. Benitez BA, Jin SC, Guerreiro R, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging 2014;35(6):1510 e1519-26
83. Guerreiro R, Bilgic B, Guven G, et al. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging 2013;34(12):2890 e2891-5
84. Lattante S, Le Ber I, Camuzat A, et al. TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia. Neurobiol Aging 2013;34(10): 2443 e2441-2
85. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 2013;8:19
86. Maher B. Personal genomes: the case of the missing heritability. Nature 2008; 456(7218):18-21
87. Aulchenko YS, Struchalin MV, Belonogova NM, et al. Predicting human height by Victorian and genomic methods. Eur J Hum Genet 2009;17(8):1070-5
88. Ibrahim-Verbaas CA, Fornage M, Bis JC, et al. Predicting stroke through genetic risk functions: the CHARGE Risk Score Project. Stroke 2014;45(2):403-12
89. Muhlenbruch K, Jeppesen C, Joost HG, et al. The value of genetic information for diabetes risk prediction-differences according to sex, age, family history and obesity. PLoS One 2013;8(5):e64307
90. Anand SS, Meyre D, Pare G, et al. Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. Diabetes Care 2013;36(9):2836-42
91. Fava C, Sjogren M, Montagnana M, et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension 2013;61(2):319-26
92. van der Net JB, Janssens AC, Sijbrands EJ, et al. Value of genetic profiling for the prediction of coronary heart disease. Am Heart J 2009;158(1):105-10
93. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet 2009;18(18): 3525-31
94. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3(1):1
95. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5(5):48
96. Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013;9(4): 438-44
97. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804
98. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2(10):975-84
99. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010; 4(1):3-14
100. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(Suppl 3):321-9
101. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6(228):228-13
102. Hampel H, Lista S, Teipel SJ, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol 2014;88(4):426-49
103. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2(8): 864-70
104. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001;301(3): 199-203
105. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999;46(3):412-16
106. van Oijen M, Hofman A, Soares HD, et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006;5(8): 655-60
107. Rosen C, Hansson O, Blennow K, et al. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 2013;8:20
108. Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008;131(Pt 5): 1252-8
109. Hoglund K, Hansson O, Buchhave P, et al. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener Dis 2008;5(5):268-76
110. Ewers M, Sperling RA, Klunk WE, et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011;34(8): 430-42
111. Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005; 65(4):565-71
112. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006;63(5):693-9
113. Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006;26(40):10222-31
114. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-19
115. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73(15): 1193-9
116. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10(5):424-35
117. Camus V, Payoux P, Barre L, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012;39(4):621-31
118. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32(7): 1207-18